Specification
Description
BMS303141 is a potent inhibitor of ATP citrate lyase (ACL). BMS-303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 μM, and lowers plasma triglycerides in a murine hyperlipdemia model.
Synonyms
BMS303141; BMS-303141; BMS 303141
IUPAC Name
3,5-dichloro-2-hydroxy-N-(4-methoxy-[1,1'-biphenyl]-3-yl)benzenesulfonamide
Canonical SMILES
O=S(C1=CC(Cl)=CC(Cl)=C1O)(NC2=CC(C3=CC=CC=C3)=CC=C2OC)=O
InChI
InChI=1S/C19H15Cl2NO4S/c1-26-17-8-7-13(12-5-3-2-4-6-12)9-16(17)22-27(24,25)18-11-14(20)10-15(21)19(18)23/h2-11,22-23H,1H3
InChI Key
SIIPNDKXZOTLEA-UHFFFAOYSA-N
Solubility
Soluble in DMSO, not in water
Appearance
White to off-white solid powder
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Biological Target
BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 53.78; H, 3.56; Cl, 16.71; N, 3.30; O, 15.08; S, 7.56
HS Tariff Code
2934.99.9001
In Vitro Activity
This study performed polyclonal activation of murine CD8+ T cells in vitro in the presence or absence of the Acly inhibitor BMS303141. This study found that inhibiting Acly during early activation results in decreased expression of early activation markers.
Reference: Cytometry A. 2020 Dec 16. https://pubmed.ncbi.nlm.nih.gov/33325591/
In Vivo Activity
BMS-303141 also suppressed osteoclast formation in vivo and prevents ovariectomy (OVX)-induced bone loss.
Reference: J Bone Miner Res. 2021 Jun 22. doi: 10.1002/jbmr.4399. https://pubmed.ncbi.nlm.nih.gov/34155695/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).